NetworkNewsBreaks

WednesdaySep 21, 2016 1:44 pm

AmeriCann, Inc. (ACAN) Launches New Line of Cannabis-Infused Products

AmeriCann (OTCQX: ACAN), developer of the proposed Massachusetts Medical Cannabis Center (MMCC) cultivation and processing facility, today unveiled its latest line of nutraceutical-grade cannabis-infused products. AmeriCann will license the intellectual property behind “Solanna” to regulated cannabis businesses looking to offer healthier alternatives to smoking, including capsules, topical lotions and balms, sublingual tinctures, oral dissolving film, trans-dermal applications, and oil cartridges for vaporizing. The company says it intends to later expand the product line to include edible products, health drinks, and branded concentrates offered at varying dosages. To view the full press release, visit: http://nnw.fm/lUwH6 About AmeriCann, Inc. AmeriCann is a…

Continue Reading

WednesdaySep 21, 2016 7:46 am

LM Funding America, Inc. (LMFA) Capitalizing on Growing U.S. Debt Collection Industry

According to data from the U.S. Federal Reserve Board (http://nnw.fm/dPEg3), roughly $3.66 trillion in consumer credit was outstanding in the United States as of July 2016. About 90 percent of these accounts are expected to be repaid pursuant to the terms of the contractual agreement, according to DBA International (http://nnw.fm/I4pf2). The remaining 10 percent, however, serve as the foundation for the massive debt collection industry, which returned approximately $44.6 billion to creditors in 2010, according to PricewaterhouseCoopers. One company operating in this lucrative industry is LM Funding America, Inc. (NASDAQ: LMFA), a specialty financing company that offers funding to nonprofit…

Continue Reading

WednesdaySep 21, 2016 7:43 am

BioLineRx Ltd. (BLRX) Initiates Phase 2a Trial for Pancreatic Cancer Therapy

BioLineRx Ltd. (NASDAQ: BLRX) announced that it has initiated a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is designed to evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA in up to 30 subjects with metastatic pancreatic adenocarcinoma. The study is designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. To view the full press release,…

Continue Reading

WednesdaySep 21, 2016 7:40 am

Airgain, Inc. (AIRG) Announces Q2 2016 Financial Results

Airgain, Inc. (NASDAQ : AIRG) today reported results for the second quarter ended June 30, 2016. Sales increased 63% to $9.9 million year over year, gross profit increased 79% to $4.5 million year over year, total operating expenses increased 31% year over year, and net income attributable to common stockholders totaled $700,428 versus a loss of $781,689 a year ago. Other key metrics include a 62% increase in total customer devises to 12 million, a 24% increase in the average number of antennas per device, and a 1% decrease in the average selling price per device. To view the full…

Continue Reading